# Atea Pharmaceuticals, Inc.: financial statements, quarterly

AVIR · Nasdaq · CIK 1593899 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/avir.md) · [Financials](/companies/avir/financials.md) · [Filings](/companies/avir/filings.md) · [Insiders](/companies/avir/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/avir/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [28.2](/filings/0000950170-24-123447.md) | [35.0 d](/filings/0000950170-25-034808.md) | [57.6](/filings/0000950170-25-069367.md) | [34.7](/filings/0000950170-25-105123.md) | [26.2](/filings/0001193125-25-277815.md) | [25.7 d](/filings/0001193125-26-094159.md) | [29.6](/filings/0001193125-26-219678.md) | [32.3](/filings/0001193125-26-347021.md) | [38.3](/filings/0001193125-25-277815.md) | [47.8 d](/filings/0001193125-26-094159.md) | [41.1](/filings/0001193125-26-219678.md) | [28.2](/filings/0001193125-26-347021.md) |
| Operating income | $m | [(40.8)](/filings/0000950170-24-123447.md) | [(46.6) d](/filings/0000950170-25-034808.md) | [(69.8)](/filings/0000950170-25-069367.md) | [(46.9)](/filings/0000950170-25-105123.md) | [(37.2)](/filings/0001193125-25-277815.md) | [(39.0) d](/filings/0001193125-26-094159.md) | [(39.0)](/filings/0001193125-26-219678.md) | [(41.3)](/filings/0001193125-26-347021.md) | [(45.6)](/filings/0001193125-25-277815.md) | [(54.9) d](/filings/0001193125-26-094159.md) | [(48.0)](/filings/0001193125-26-219678.md) | [(35.1)](/filings/0001193125-26-347021.md) |
| Income tax | $m | [0.2](/filings/0000950170-24-123447.md) | [0.3 d](/filings/0000950170-25-034808.md) | [0.2](/filings/0000950170-25-069367.md) | [0.2](/filings/0000950170-25-105123.md) | [0.2](/filings/0001193125-25-277815.md) | [0.2 d](/filings/0001193125-26-094159.md) | [0.2](/filings/0001193125-26-219678.md) | [0.2](/filings/0001193125-26-347021.md) | [0.2](/filings/0001193125-25-277815.md) | [(6.8) d](/filings/0001193125-26-094159.md) | [0.1](/filings/0001193125-26-219678.md) | [0.0](/filings/0001193125-26-347021.md) |
| Net income | $m | [(33.1)](/filings/0000950170-24-123447.md) | [(39.2) d](/filings/0000950170-25-034808.md) | [(63.2)](/filings/0001193125-25-277815.md) | [(40.5)](/filings/0001193125-25-277815.md) | [(31.2)](/filings/0001193125-25-277815.md) | [(33.5) d](/filings/0001193125-26-094159.md) | [(34.3)](/filings/0001193125-26-347021.md) | [(37.2)](/filings/0001193125-26-347021.md) | [(42.0)](/filings/0001193125-25-277815.md) | [(44.9) d](/filings/0001193125-26-094159.md) | [(45.4)](/filings/0001193125-26-347021.md) | [(32.9)](/filings/0001193125-26-347021.md) |
| Diluted EPS | $ per share | [(0.40)](/filings/0000950170-24-123447.md) | not reported | [(0.75)](/filings/0000950170-25-069367.md) | [(0.48)](/filings/0000950170-25-105123.md) | [(0.37)](/filings/0001193125-25-277815.md) | not reported | [(0.40)](/filings/0001193125-26-219678.md) | [(0.44)](/filings/0001193125-26-347021.md) | [(0.53)](/filings/0001193125-25-277815.md) | not reported | [(0.57)](/filings/0001193125-26-219678.md) | [(0.41)](/filings/0001193125-26-347021.md) |
| Basic EPS | $ per share | [(0.40)](/filings/0000950170-24-123447.md) | not reported | [(0.75)](/filings/0000950170-25-069367.md) | [(0.48)](/filings/0000950170-25-105123.md) | [(0.37)](/filings/0001193125-25-277815.md) | not reported | [(0.40)](/filings/0001193125-26-219678.md) | [(0.44)](/filings/0001193125-26-347021.md) | [(0.53)](/filings/0001193125-25-277815.md) | not reported | [(0.57)](/filings/0001193125-26-219678.md) | [(0.41)](/filings/0001193125-26-347021.md) |

- Revenue: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [138](/filings/0000950170-23-061213.md) | [144](/filings/0000950170-25-034808.md) | [161](/filings/0000950170-24-059699.md) | [243](/filings/0000950170-24-092914.md) | [98.5](/filings/0000950170-24-123447.md) | [64.7](/filings/0001193125-26-094159.md) | [119](/filings/0000950170-25-069367.md) | [87.7](/filings/0000950170-25-105123.md) | [77.3](/filings/0001193125-25-277815.md) | [95.7](/filings/0001193125-26-347021.md) | [79.3](/filings/0001193125-26-219678.md) | [76.5](/filings/0001193125-26-347021.md) |
| Current assets | $m | [603](/filings/0000950170-23-061213.md) | [590](/filings/0000950170-25-034808.md) | [549](/filings/0000950170-24-059699.md) | [506](/filings/0000950170-24-092914.md) | [487](/filings/0000950170-24-123447.md) | [462](/filings/0001193125-26-094159.md) | [434](/filings/0000950170-25-069367.md) | [386](/filings/0000950170-25-105123.md) | [336](/filings/0001193125-25-277815.md) | [311](/filings/0001193125-26-347021.md) | [263](/filings/0001193125-26-219678.md) | [229](/filings/0001193125-26-347021.md) |
| Total assets | $m | [608](/filings/0000950170-23-061213.md) | [595](/filings/0000950170-25-034808.md) | [553](/filings/0000950170-24-059699.md) | [510](/filings/0000950170-24-092914.md) | [491](/filings/0000950170-24-123447.md) | [465](/filings/0001193125-26-094159.md) | [440](/filings/0000950170-25-069367.md) | [392](/filings/0000950170-25-105123.md) | [343](/filings/0001193125-25-277815.md) | [315](/filings/0001193125-26-347021.md) | [267](/filings/0001193125-26-219678.md) | [232](/filings/0001193125-26-347021.md) |
| Current liabilities | $m | [18.9](/filings/0000950170-23-061213.md) | [32.4](/filings/0000950170-25-034808.md) | [41.3](/filings/0000950170-24-059699.md) | [26.6](/filings/0000950170-24-092914.md) | [25.2](/filings/0000950170-24-123447.md) | [18.6](/filings/0001193125-26-094159.md) | [21.7](/filings/0000950170-25-069367.md) | [20.1](/filings/0000950170-25-105123.md) | [20.2](/filings/0001193125-25-277815.md) | [39.8](/filings/0001193125-26-347021.md) | [33.4](/filings/0001193125-26-219678.md) | [28.1](/filings/0001193125-26-347021.md) |
| Total liabilities | $m | [26.3](/filings/0000950170-23-061213.md) | [39.8](/filings/0000950170-25-034808.md) | [48.7](/filings/0000950170-24-059699.md) | [33.9](/filings/0000950170-24-092914.md) | [32.4](/filings/0000950170-24-123447.md) | [25.8](/filings/0001193125-26-094159.md) | [28.9](/filings/0000950170-25-069367.md) | [27.2](/filings/0000950170-25-105123.md) | [27.2](/filings/0001193125-25-277815.md) | [39.8](/filings/0001193125-26-094159.md) | not reported | not reported |
| Shareholders' equity | $m | [582](/filings/0000950170-24-123447.md) | [555](/filings/0001193125-26-094159.md) | [504](/filings/0001193125-25-277815.md) | [476](/filings/0001193125-25-277815.md) | [459](/filings/0001193125-25-277815.md) | [439](/filings/0001193125-26-347021.md) | [411](/filings/0001193125-26-347021.md) | [364](/filings/0001193125-26-347021.md) | [316](/filings/0001193125-25-277815.md) | [275](/filings/0001193125-26-347021.md) | [234](/filings/0001193125-26-347021.md) | [204](/filings/0001193125-26-347021.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(17.6) d](/filings/0000950170-24-123447.md) | [(21.8) d](/filings/0000950170-25-034808.md) | [(39.9)](/filings/0000950170-25-069367.md) | [(42.2) d](/filings/0000950170-25-105123.md) | [(23.0) d](/filings/0001193125-25-277815.md) | [(30.4) d](/filings/0001193125-26-094159.md) | [(30.6)](/filings/0001193125-26-219678.md) | [(32.9) d](/filings/0001193125-26-347021.md) | [(40.4) d](/filings/0001193125-25-277815.md) | [(28.2) d](/filings/0001193125-26-094159.md) | [(46.4)](/filings/0001193125-26-219678.md) | [(37.1) d](/filings/0001193125-26-347021.md) |
| Capital expenditure | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [11.4 d](/filings/0001193125-25-277815.md) | [0.0 d](/filings/0001193125-26-094159.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: not reported
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [83.3](/filings/0000950170-23-061213.md) | [83.3](/filings/0000950170-24-059699.md) | [83.4](/filings/0000950170-24-092914.md) | [83.4](/filings/0000950170-24-123447.md) | [83.9](/filings/0000950170-25-069367.md) | [84.3](/filings/0000950170-25-105123.md) | [84.4](/filings/0001193125-25-277815.md) | [85.2](/filings/0001193125-26-219678.md) | [83.7](/filings/0001193125-26-347021.md) | [79.1](/filings/0001193125-25-277815.md) | [79.2](/filings/0001193125-26-219678.md) | [80.1](/filings/0001193125-26-347021.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 80,204,699 at 2026-08-10, from the cover of the [10-Q filed 2026-08-12](/filings/0001193125-26-347021.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:43 ET. No prices; not investment advice.